Contineum Says US FDA Clears IND Application for PIPE-791 to Treat Chronic Pain Linked to Osteoarthritis, Low Back Pain

MT Newswires Live

18 Nov 2024

Contineum Therapeutics (CTNM) said Monday the US Food and Drug Administration approved its investigational new drug application for PIPE-791 to treat chronic pain related to osteoarthritis and low back pain.

The phase 1b trial to potentially treat the two indications is expected to start in Q1 2025, the company said, adding it expects to enroll about 40 people at up to five sites.

Topline results from the trial are expected in early 2026, Contineum said.

Price: 16.50, Change: -0.71, Percent Change: -4.13

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

no data

No relevant data is available

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/news/2484631671"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2484631671\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2484631671?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2024-11-18 23:06","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484631671","market":"hk","top_or_hot":-1,"title":"Contineum Says US FDA Clears IND Application for PIPE-791 to Treat Chronic Pain Linked to Osteoarthritis, Low Back Pain","media":"MT Newswires Live","content":"<html><body><p> Contineum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CTNM) said Monday the US Food and Drug Administration approved its investigational new drug application for PIPE-791 to treat chronic pain related to osteoarthritis and low back pain.</p><p>The phase 1b trial to potentially treat the two indications is expected to start in Q1 2025, the company said, adding it expects to enroll about 40 people at up to five sites.</p><p>Topline results from the trial are expected in early 2026, Contineum said.</p><p>Price: 16.50, Change: -0.71, Percent Change: -4.13</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Contineum Says US FDA Clears IND Application for PIPE-791 to Treat Chronic Pain Linked to Osteoarthritis, Low Back Pain</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nContineum Says US FDA Clears IND Application for PIPE-791 to Treat Chronic Pain Linked to Osteoarthritis, Low Back Pain\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2024-11-18 23:06</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> Contineum <a href=\"https://laohu8.com/S/LENZ\">Therapeutics</a> (CTNM) said Monday the US Food and Drug Administration approved its investigational new drug application for PIPE-791 to treat chronic pain related to osteoarthritis and low back pain.</p><p>The phase 1b trial to potentially treat the two indications is expected to start in Q1 2025, the company said, adding it expects to enroll about 40 people at up to five sites.</p><p>Topline results from the trial are expected in early 2026, Contineum said.</p><p>Price: 16.50, Change: -0.71, Percent Change: -4.13</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4007","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2484631671","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484631671","pubTimestamp":1731942374,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Contineum Therapeutics  said Monday the US Food and Drug Administration approved its investigational new drug application for PIPE-791 to treat chronic pain related to osteoarthritis and low back pain.The phase 1b trial to potentially treat the two indications is expected to start in Q1 2025, the company said, adding it expects to enroll about 40 people at up to five sites.Topline results from the trial are expected in early 2026, Contineum said.Price: 16.50, Change: -0.71, Percent Change: -4.13","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4007":"制药","CTNM":"Contineum Therapeutics, INC."},"translate_title":"Contineum表示美国FDA批准PIPE-791的IND申请，用于治疗与骨关节炎、腰痛相关的慢性疼痛","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"CTNM":0.9},"content_text":"Contineum Therapeutics (CTNM) said Monday the US Food and Drug Administration approved its investigational new drug application for PIPE-791 to treat chronic pain related to osteoarthritis and low back pain.The phase 1b trial to potentially treat the two indications is expected to start in Q1 2025, the company said, adding it expects to enroll about 40 people at up to five sites.Topline results from the trial are expected in early 2026, Contineum said.Price: 16.50, Change: -0.71, Percent Change: -4.13","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":1}}}

If the download button clicks without skipping, click on the top right menu and select "Open in Browser."

Consult now
Download APP
Scan QR code to download the app.